Skip to main content
Evidence Snapshot

Influenza A virus

CHEMBL613740 ORGANISM Influenza A virus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613740
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Influenza A virus as ChEMBL target CHEMBL613740. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Influenza A virus
ORGANISM · Influenza A virus
As of 2026-09-13
ChEMBL target ID
CHEMBL613740
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Influenza A virus matters

As of 2026-09-13

Influenza A virus is reviewed as Influenza A virus; the current evidence base includes 27 approved drugs, 5578 compounds, and 2672 assays, with lead potency reaching pChEMBL 10.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 27 approved drugs, 5578 compounds, and 2672 assays for this target. The dominant activity type is EC50. CHEMBL222813 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL222813 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
27 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Influenza A virus matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5578
Total Compounds
2672
Total Assays
27
Approved Drugs
IC50: 3151.0, EC50: 4528.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL222813
 10.4 IC50 Approved
No preferred name
CHEMBL3818159
 10.4 IC50 —
No preferred name
CHEMBL290814
 10.2 IC50 —
No preferred name
CHEMBL139367
 10.1 IC50 Approved
No preferred name
CHEMBL222813
 10.0 EC50 Approved

Approved Drugs

Structure Compound First Approval
SELUMETINIB
CHEMBL1614701
 2020
PERAMIVIR ANHYDROUS
CHEMBL139367
 2014
FAVIPIRAVIR
CHEMBL221722
 2014
TRAMETINIB
CHEMBL2103875
 2013
REGORAFENIB
CHEMBL1946170
 2012
ZANAMIVIR
CHEMBL222813
 1999
OSELTAMIVIR
CHEMBL1229
 1999
OSELTAMIVIR PHOSPHATE
CHEMBL1200340
 1999
GEMCITABINE
CHEMBL888
 1996
RIMANTADINE
CHEMBL959
 1993
RIBAVIRIN
CHEMBL1643
 1985
AMANTADINE
CHEMBL660
 1968
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613740